Company profile
Glass House Brands Inc
NYSE: GLAS · Healthcare · Drug Manufacturers - Specialty & Generic
#298 of 1,418 Healthcare companies by revenue
EA Score
——FH 61DQ —GM —SS 53
v0.1 · 35/100 weight · pillars only
↑ workforce scale, market scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$163.2M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$29.7M
Employees
392
as of 2026-09-01
Market cap
$691.4M
as of 2026-09-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$182.0M$182.0M2025
Net income-$29.7M-$29.7M2025
Operating income-$14.6M-$14.6M2025
Total assets$318.6M$318.6M2025
Liabilities$236.5M$236.5M2025
Equity$73.9M$73.9M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Glass House Brands Inc’s revenue?
Glass House Brands Inc booked $182.0M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -16.3% net margin.
Peers · Healthcare
Rhythm Pharmaceuticals, Inc.60CMaravai LifeSciences Holdings, Inc.53DStoke Therapeutics, Inc.60CHeartflow, Inc. Common Stock44DPhathom Pharmaceuticals, Inc.47DSyndax Pharmaceuticals, Inc.52DNeighbors
Los Angeles →Key facts
CEOKyle Kazan
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLong Beach, CA
ExchangeNYSE: GLAS
Employees392
IPO date2026-06-30
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.